Furthermore, both the FGFR3 and p53 high expression groups also demonstrated that they would still yield favorable outcomes in MIBC patients, while no significant differences were observed in UTUC patients (p = 0.077 and 0.218, respectively). The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.